OakChart

Benitec Biopharma Inc

BNTCHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 3:59 PM ET

9.47+0.19 (2.05%)
2026-11-12 03:57 CET
Market cap
330.40 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-45.55 USD m
Free cash flow, TTM
-17.40 USD m
EPS diluted, TTM
-1.09
P/E
-
Compare

Price

BNTC against its 20, 50 and 200-day averages
2050200missearnings
8.0010.0012.0014.00634K1.3MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26BNTCclose 9.4720-day 8.8350-day 9.81200-day 11.429.4752w high52w low

34.2% under the 52-week high of 14.39 on 31 Dec 2025. 52-week low 7.89 on 28 Oct 2026. Last 15 sessions, 29.7% high to low

Volume 0.63× normal · the line is the 50-bar volume average

Profile

BNTC
52-week range, 24% of the way up
7.8914.39

Benitec Biopharma, Inc. is a development-stage biotechnology company, which engages in the advancement of novel genetic medicines. Its proprietary platforms include DNA-directed RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitates sustained silencing of disease-causing genes following a single administration. It is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy and Chronic Hepatitis B. The company was founded in 1995 and is headquartered in Hayward, CA.

IndexRUT
Employees24
IPOJun 23, 2014
Beta0.23
ATR, 14d0.69
Rel volume0.63
Short float5.86%
Insider own2.51%
Inst own98.95%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap330.41M
Enterprise Value151.08M
Income-45.55M
Sales0.00M
Book/sh5.14
Cash/sh5.16
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees24
IPOJun 23, 2014

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B1.84
P/C1.83
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio34.00
Current Ratio34.00
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.09
EPS next Y-1.49
EPS next Q-0.28
EPS this Y-26.28%
EPS next Y-20.00%
EPS next 5Y-11.27%
EPS past 3/5Y58.92% 55.32%
Sales past 3/5Y- -
EPS Y/Y TTM14.04%
Sales Y/Y TTM-
EPS Q/Q-74.01%
Sales Q/Q-
EarningsSep 14 AMC
EPS/Sales Surpr.-1.21% -

Ownership

Insider Own2.51%
Insider Trans0.00%
Inst Own98.95%
Inst Trans0.80%
ROA-32.28%
ROE-33.21%
ROIC-25.69%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA207.28%
SMA50-3.51%
SMA200-17.06%
Trades-

Technical

Shs Outstand34.42M
Shs Float34.01M
Short Float5.86%
Short Ratio10.37
Short Interest1.99M
52W High14.39 -34.19%
52W Low7.89 20.10%
Volatility8.77% 7.59%
ATR (14)0.69
RSI (14)52.96
Beta0.23
Rel Volume0.63
Avg Volume192.28K
Volume120,642

Performance

Perf Week2.05%
Perf Month9.73%
Perf Quarter-24.60%
Perf Half Y-18.71%
Perf YTD-29.70%
Perf Year-28.58%
Perf 3Y176.90%
Perf 5Y-83.85%
Perf 10Y-97.62%
Recom1.25
Target Price23.29
Prev Close9.28
Price9.47
Change %2.05%

Analyst ratings

latest 10 of 16
DateActionAnalystRating changeTargetImplied
Oct 23, 2026InitiatedRRaymond JamesOutperform$14+47.8%
Jul 28, 2026InitiatedWWedbushOutperform$16+69.0%
Jun 10, 2026DowngradeGGuggenheimBuy → Neutral
May 12, 2026InitiatedEEvercore ISIOutperform$25+164.0%
Jul 07, 2025InitiatedTTD CowenBuy
Dec 16, 2024InitiatedHH.C. WainwrightBuy$28+195.7%
Dec 13, 2024InitiatedRRobert W. BairdOutperform$30+216.8%
Oct 16, 2024InitiatedOOppenheimerOutperform$35+269.6%
Sep 12, 2024InitiatedGGuggenheimBuy$17+79.5%
Jul 22, 2024InitiatedLLeerink PartnersOutperform$13+37.3%

Peers

Mkt cap
TickerCompanyMkt cap
DYNDyne Therapeutics Inc3.37B
SLDBSolid Biosciences Inc848.24M
RGNXRegenxbio Inc560.06M
WVEWave Life Sciences Inc674.52M
SRPTSarepta Therapeutics Inc1.79B
TRDAEntrada Therapeutics Inc212.98M
PEPGPepGen Inc364.31M
CAPRCapricor Therapeutics Inc652.32M
QUREuniQure NV1.72B
TSHATaysha Gene Therapies Inc1.39B

Insider trading

6 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
SUVRETTA CAPITAL MANAGEMENT, LDirectorDec 29 '25Buy13.4477,3871,040,0819,700,195Dec 29 07:31 PM
SUVRETTA CAPITAL MANAGEMENT, LDirectorDec 23 '25Buy12.8550,000642,5009,620,075Dec 29 07:31 PM
SUVRETTA CAPITAL MANAGEMENT, LDirectorDec 26 '25Buy13.1016,836220,5529,634,395Dec 29 07:31 PM
SUVRETTA CAPITAL MANAGEMENT, LDirectorDec 22 '25Buy12.0819,542236,0679,577,475Dec 22 07:45 PM
SUVRETTA CAPITAL MANAGEMENT, LDirectorDec 19 '25Buy11.4816,384188,0889,560,825Dec 22 07:45 PM
SUVRETTA CAPITAL MANAGEMENT, LDirectorDec 18 '25Buy11.2410,215114,8179,546,875Dec 22 07:45 PM

Held by

AUM
TickerCompanyAUM
PINKSimplify Health Care ETFAUM: 350.61M
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IWCiShares Micro-Cap ETFAUM: 1.22B
GNOMGlobal X Genomics & Biotechnology ETFAUM: 105.76M
AVSCAvantis U.S Small Cap Equity ETFAUM: 3.23B
VTWVVanguard Russell 2000 Value Index ETFAUM: 1.29B

News

latest 14 of 198
  • Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 (GlobeNewswire)
  • Benitec Biopharma Announces Regulatory Update Following Type C Meeting with FDA for BB-301 Pivotal Study (GlobeNewswire)
  • Benitec Biopharma Releases Full Year 2026 Financial Results and Provides Operational Update (GlobeNewswire) -8.53%
  • Benitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update (GlobeNewswire)
  • Benitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meeting (GlobeNewswire)
  • PureTech Founded Entity Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of Directors (Business Wire)
  • Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference (GlobeNewswire) +10.67%
  • Benitec Biopharma Announces Acceptance of Late- Breaking Abstract for the BB-301 Phase 1b/2a Clinical Treatment Study at the Muscular Dystrophy Association Clinical & Scientific Conference (GlobeNewswire)
  • Benitec Biopharma Releases Second Quarter 2026 Financial Results and Provides Operational Update (GlobeNewswire)
  • Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response (GlobeNewswire)
  • Does Benitec Biopharma (BNTC) Have the Potential to Rally 83.87% as Wall Street Analysts Expect? (Zacks)
  • Wall Street Analysts Predict an 87.48% Upside in Benitec Biopharma (BNTC): Here's What You Should Know (Zacks)
  • Down 25.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Benitec Biopharma (BNTC) (Zacks) +7.98%
  • Citizens Lifts Benitec Biopharma Inc. (BNTC) Price Target on Topline Results for Oculopharyngeal Muscular Dystrophy Treatment (Insider Monkey)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q42026-09-14-0.268-0.264-0.2600.000.007
2026Q32026-05-14-0.240-0.268-0.2420.000.006
2026Q22026-02-12-0.260-0.223-0.2580.000.006
2026Q12025-11-14-0.220-0.450-0.2160.000.007
2025Q42025-09-22-0.357-0.310-0.2140.000.008
2025Q32025-05-14-0.240-0.348-0.2420.000.006
2025Q22025-02-14-0.330-0.776-0.3330.000.007
2025Q12024-11-14-0.480-0.550-0.4750.000.003
2024Q42024-09-261.040-0.488-0.5290.000.004
2024Q32024-05-13-1.640-0.780-1.6360.000.001
2024Q22024-02-13-2.640-0.390-2.6390.000.001
2024Q12023-11-13-2.760-0.510-2.7600.000.001
2023Q42023-09-21-0.010-3.230-2.8320.020.001
2023Q32023-05-15-2.720-3.400-2.6710.050.001
2023Q22023-02-13-3.400-1.870-3.3370.010.001
2023Q12022-11-10-7.990-3.145-7.9760.000.012

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY-137.7--137.740.10-
2021FY-54.910--54.9410.06-
2022FY-37.910-32.130-37.8790.070.10
2023FY-14.120-13.260-14.1160.080.00
2024FY-6.000-4.790-5.5100.000.00
2025FY-1.050-1.248-1.0470.000.00
2026FY-0.980-0.978-0.9800.000.00
2027FY--1.238--0.00
2028FY--1.485--17.78
2029FY--1.350--0.00
2030FY--0.977--55.33
2031FY-0.893--221.79

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2027Q1S2026-10-216000.000.000.00
2027Q1S2026-09-255000.000.000.00
2027Q1S2026-09-154000.000.000.00
2027Q1S2026-07-274000.000.000.00
2027Q1S2026-05-143000.000.000.00
2027Q1S2026-02-273000.000.000.00
2027Q1S2026-02-122000.000.000.00
2027Q1S2025-12-082000.000.000.00
2027Q1S2025-11-173000.000.000.00
2027Q1S2025-11-112000.000.000.00
2027Q1S2025-11-102000.000.000.00
2027Q1S2025-11-092000.000.000.00
2027Q1S2025-11-082000.000.000.00
2027Q1S2025-11-072000.000.000.00

Estimate history

EPS, annual-3299.476776.521-137.739-54.941-37.879-14.116-5.51-1.047-0.978
Period201820192020202120222023202420252026
EPS, quarterly-0.529-0.475-0.333-0.242-0.214-0.216-0.258-0.242-0.372
PeriodQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26Q4 '26
Sales, annual0.29211.5510.0970.0590.0730.075000
Period201820192020202120222023202420252026
Sales, quarterly000000000
PeriodQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26Q4 '26
Shares, annual0.0030.0030.0650.4810.4811.64610.08626.2534.417
Period201820192020202120222023202420252026
Shares, quarterly10.08617.89423.45125.54626.2526.2534.25534.35434.417
PeriodQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26Q4 '26

Income statement, annual

Currency USD, millions
MetricTTM2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue0.000.000.000.000.070.070.060.1011.55
Cost of Goods Sold Incl. D&A0.480.480.400.340.380.400.550.190.44
Gross Profit-0.48-0.48-0.40-0.34-0.31-0.33-0.49-0.0911.12
Selling, General and Administrative Excl. Other50.7150.7141.3722.2618.7817.5313.118.199.18
Research and Development23.3923.3918.3315.6112.7711.277.023.004.57
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-51.19-51.19-41.77-22.60-19.08-17.85-13.60-8.291.94
Interest Expense0.000.000.000.000.030.000.000.000.00
Unusual Expense0.000.00-0.760.000.000.01-0.020.000.02
Net Income Before Taxes-45.55-45.55-37.92-21.75-19.56-18.21-13.88-8.281.96
Income Taxes0.000.000.000.000.000.000.00-0.01-0.65
Consolidated Net Income-45.55-45.55-37.92-21.75-19.56-18.21-13.88-8.272.61
Net Income From Continuing Operations-45.55-45.55-37.92-21.75-19.56-18.21-13.88-8.272.61
Net Income-45.55-45.55-37.92-22.37-19.56-18.21-13.88-8.272.61
EPS (Recurring)-1.32-0.98-1.06-5.51-14.11-37.86-54.99-137.73780.89
EPS (Basic, Before Extraordinaries)-1.09-0.98-1.05-5.51-14.12-37.88-54.94-137.74776.52
EPS (Diluted)-1.09-0.98-1.05-5.51-14.12-37.88-54.94-137.74776.52
EBITDA-50.71-50.71-41.37-22.25-18.70-17.46-13.17-7.912.09
Non-Operating Income (Expense)5.655.653.080.85-0.45-0.34-0.300.010.05
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense26.4126.4117.430.830.450.870.630.240.67
Price To Earnings Ratio--------174.50
Price To Sales Ratio----74.92129.85309.4283.270.06
Gross Margin-----408.00-449.32-827.12-94.8596.23
Operating Margin-----25,441.33-24,457.53-23,044.07-8,542.2716.75
Net Margin-----26,082.67-24,942.47-23,528.81-8,529.9022.59
Shares Outstanding34.4234.4226.2510.091.650.480.480.070.00
Market Capitalization330.40330.40307.1319.056.679.4834.735.65192.49

Income statement, quarterly

Currency USD, millions
Metric2026Q42026Q32026Q22026Q12025Q42025Q32025Q22025Q1
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.120.120.120.120.120.110.080.09
Gross Profit-0.12-0.12-0.12-0.12-0.12-0.11-0.08-0.09
Selling, General and Administrative Excl. Other14.3113.4613.269.699.7210.088.535.70
Research and Development7.896.305.833.372.875.985.073.59
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-14.43-13.58-13.38-9.80-9.83-10.19-8.61-5.79
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.00-0.760.00
Net Income Before Taxes-12.81-11.94-11.84-8.97-8.81-9.35-7.36-5.06
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-12.81-11.94-11.84-8.97-8.81-9.35-7.36-5.06
Net Income From Continuing Operations-12.81-11.94-11.84-8.97-8.81-9.35-7.36-5.06
Net Income-12.81-11.94-11.84-8.97-8.81-9.35-7.36-5.06
EPS (Recurring)-0.37-0.24-0.26-0.22-0.21-0.24-0.36-0.48
EPS (Basic, Before Extraordinaries)-0.37-0.24-0.26-0.22-0.21-0.24-0.33-0.48
EPS (Diluted)-0.37-0.24-0.26-0.22-0.21-0.24-0.33-0.48
EBITDA-14.31-13.46-13.26-9.69-9.72-10.08-8.53-5.70
Non-Operating Income (Expense)1.621.651.540.841.030.830.490.73
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense6.267.597.385.1813.452.600.940.44
Shares Outstanding34.4234.3534.2526.2526.2525.5523.4517.89
Market Capitalization330.40365.87456.12368.29307.13331.68293.2292.69

Balance sheet, annual

Currency USD, millions
Metric2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Cash & Short Term Investments180.0997.8650.932.494.0819.779.8015.7211.90
Short Term Receivables0.000.030.230.060.000.030.062.543.14
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets1.600.630.521.180.740.810.950.500.39
Total Current Assets181.6998.5251.673.734.8220.6110.8118.7615.43
Net Property, Plant & Equipment0.870.990.450.610.990.580.770.470.24
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Intangible Assets------0.000.000.00
Deferred Tax Assets------0.16--
Other Assets0.070.080.090.120.160.190.010.010.09
Total Assets182.6299.5952.214.465.9721.3811.7419.2415.76
Short Term Debt Incl. Current Port. of LT Debt0.500.350.280.280.250.210.190.000.00
Accounts Payable0.910.201.353.231.880.270.281.470.43
Other Current Liabilities3.941.253.290.470.400.880.661.171.45
Total Current Liabilities5.341.804.923.982.531.371.142.641.88
Long Term Debt0.270.500.000.280.560.000.210.000.00
Provision for Risks Charges0.000.000.040.000.000.000.000.000.00
Deferred Tax Liabilities------0.16--
Other Liabilities0.000.000.000.000.000.000.000.000.04
Total Liabilities5.612.304.964.263.091.371.512.641.92
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity177.0197.3047.250.202.8820.0110.2416.5913.84
Total Shareholders Equity177.0197.3047.250.202.8820.0110.2416.5913.84
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity177.0197.3047.250.202.8820.0110.2416.5913.84
Total Liabilities & Stockholders Equity182.6299.5952.214.465.9721.3811.7419.2415.76
Book Value Per Share5.143.714.680.126.0041.63157.034,938.894,120.41
Tangible Book Value Per Share5.143.714.680.126.0041.63157.034,938.894,120.41
Full-Time Employees24191618181414--
Price to Book Ratio1.843.061.6633.043.291.740.469.7333.38
Return on Assets-32.28-49.96-76.76-374.86-133.14-83.82-53.4214.91-54.77
Return on Equity-33.21-52.46-91.68-1,268.61-159.08-91.79-61.6717.14-59.83
Return on Invested Capital-25.69-38.77-46.04-4,025.10-529.15-69.38-79.1715.72-65.57
Quick Ratio34.0054.6710.490.941.9015.059.517.108.21
Current Ratio34.0054.6710.490.941.9015.059.517.108.21

Cash flow, annual

Currency USD, millions
MetricTTM2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income-47.69-45.55-37.92-21.75-19.56-18.21-13.88-8.272.61
Depreciation0.500.480.400.340.380.390.420.370.16
Other Funds (Non Cash)27.6526.4116.660.830.460.880.620.240.70
Funds from Operations-19.53-18.66-20.86-20.58-18.73-16.94-12.84-7.663.47
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital2.242.14-2.731.170.711.040.010.131.32
Cash from Operating Activities-17.29-16.52-23.59-19.40-18.01-15.90-12.83-7.544.79
Capital Expenditures-0.11-0.11-0.02-0.18-0.00-0.01-0.22-0.10-0.40
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-0.11-0.11-0.02-0.18-0.00-0.01-0.22-0.09-0.40
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock103.6398.9870.4968.0316.020.0022.521.770.00
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock103.6398.9870.4968.0316.020.0022.521.770.00
Proceedsfrom Stock Options102.8498.2370.4968.0316.020.0022.521.770.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities103.6398.9870.4968.0316.020.0022.521.770.00
Exchange Rate Effect-0.13-0.130.05-0.010.410.200.50-0.06-0.55
Net Change in Cash86.0982.2346.9348.44-1.59-15.719.97-5.923.84
Free Cash Flow-17.40-16.62-23.61-19.58-18.01-15.91-13.05-7.634.39
Preferred Dividends (Cash Flow)-0.000.00-0.000.000.000.000.00
Price to Free Cash Flow--------0.15
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q42026Q32026Q22026Q12025Q42025Q3
Cash & Short Term Investments180.09184.88188.9094.5997.86103.65
Short Term Receivables0.000.000.130.010.030.00
Inventories0.000.000.000.000.000.00
Other Current Assets1.601.140.560.480.630.36
Total Current Assets181.69186.02189.6095.0898.52104.01
Net Property, Plant & Equipment0.870.921.020.870.991.11
Total Investments and Advances0.000.000.000.000.000.00
Other Assets0.070.070.070.070.080.09
Total Assets182.62187.00190.6896.0399.59105.21
Short Term Debt Incl. Current Port. of LT Debt0.500.480.470.410.350.35
Accounts Payable0.910.641.020.270.200.43
Other Current Liabilities3.942.161.321.341.256.25
Total Current Liabilities5.343.272.802.031.807.03
Long Term Debt0.270.390.520.400.500.61
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities5.613.673.322.432.307.64
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity177.01183.33187.3693.6097.3097.57
Total Shareholders Equity177.01183.33187.3693.6097.3097.57
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity177.01183.33187.3693.6097.3097.57
Total Liabilities & Stockholders Equity182.62187.00190.6896.0399.59105.21
Book Value Per Share5.145.345.473.573.713.82
Tangible Book Value Per Share5.145.345.473.573.713.82
Full-Time Employees24---19-
Price to Book Ratio1.841.953.783.793.064.02
Return on Assets-32.28-28.43-28.89-41.85-40.28-44.07
Return on Equity-33.21-29.58-29.59-43.71-42.31-48.57
Return on Invested Capital-7.23-6.50-6.30-9.54-9.00-9.53
Quick Ratio34.0056.8267.6946.9554.6714.80
Current Ratio34.0056.8267.6946.9554.6714.80

Cash flow, quarterly

Currency USD, millions
Metric2026Q42026Q32026Q22026Q12025Q42025Q3
Net Income-13.61-13.23-11.87-8.97-16.49-8.78
Depreciation0.130.130.120.120.120.10
Other Funds (Non Cash)6.688.397.405.1813.392.50
Funds from Operations-6.80-4.71-4.35-3.67-2.98-6.18
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital1.56-0.200.560.32-5.513.46
Cash from Operating Activities-5.24-4.91-3.79-3.35-8.49-2.72
Capital Expenditures-0.08-0.02-0.010.00-0.00-0.01
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.08-0.02-0.010.00-0.00-0.01
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.864.3698.410.004.1226.62
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.864.3698.410.004.1226.62
Proceedsfrom Stock Options0.603.8398.410.004.1226.62
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.864.3698.410.004.1226.62
Exchange Rate Effect-0.01-0.07-0.130.09-0.11-0.02
Net Change in Cash-4.48-0.6494.48-3.27-4.4923.87
Free Cash Flow-5.32-4.93-3.80-3.35-8.49-2.73

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-305.86%2.0M34.0M176.39K
2026-10-155.86%2.0M34.0M159.37K
2026-09-306.00%2.0M34.0M142.69K
2026-09-156.43%2.2M34.0M144.18K
2026-08-316.61%2.2M33.5M139.27K
2026-08-146.29%2.1M33.5M126.66K
2026-07-316.41%2.1M33.5M108.51K
2026-07-156.78%2.3M33.5M113.86K
2026-06-306.66%2.2M33.5M115.50K
2026-06-157.19%2.4M33.4M109.49K
2026-05-296.98%2.3M33.4M137.89K
2026-05-156.74%2.3M33.4M151.03K
2026-04-307.10%2.3M32.7M156.96K
2026-04-156.94%2.3M32.7M157.65K
2026-03-317.07%2.3M32.6M164.55K
2026-03-136.60%2.2M32.6M177.42K
2026-02-276.19%2.0M32.6M180.23K
2026-02-136.51%2.1M32.6M183.85K
2026-01-306.35%2.1M32.9M241.98K
2026-01-155.89%1.9M32.9M228.72K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.504.909.000.0020.9960.000.000.985-0.0160.001
call5.003.006.503.609.7326.000.000.969-0.0150.001
call7.500.104.900.007.7530.000.000.827-0.0410.004
call10.000.004.901.009.7041.000.000.759-0.2390.005
call12.500.004.900.0010.6730.000.000.747-0.2750.005
call15.000.004.900.0011.3950.000.000.736-0.3000.005
call17.500.004.900.0011.9680.000.000.728-0.3200.005
call20.000.004.900.0012.4400.000.000.722-0.3360.005
call22.500.004.900.0012.8400.000.000.718-0.3490.005
put2.500.004.900.000.0000.000.00-0.019-0.0780.001
put5.000.000.050.002.3540.000.00-0.032-0.0140.001
put7.500.000.300.2512.81431.000.00-0.132-0.2200.003
put10.000.004.900.008.1770.000.00-0.241-0.2380.005
put12.501.004.900.004.7810.000.00-0.265-0.2800.005
put15.003.507.600.005.9560.000.00-0.277-0.3070.005
put17.506.009.600.005.7360.000.00-0.285-0.3280.005
put20.008.5012.500.006.9460.000.00-0.292-0.3450.005
put22.5011.0014.800.007.0350.000.00-0.297-0.3590.005

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-288-KCurrent report2026-10-28SEC
2026-10-20DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-10-20DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-10-20SEC
2026-10-058-KCurrent report2026-10-05SEC
2026-09-308-KCurrent report2026-09-29SEC
2026-09-248-KCurrent report2026-09-18SEC
2026-09-21EFFECTEffectiveness filing by commission orderSEC
2026-09-14S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-09-1410-KAnnual report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-09-148-KCurrent report2026-09-14SEC
2026-06-304Statement of changes in beneficial ownership of securities2026-06-29SEC
2026-05-298-KCurrent report2026-05-22SEC
2026-05-284Statement of changes in beneficial ownership of securities2026-05-26SEC
2026-05-283Initial statement of beneficial ownership of securities2026-05-22SEC
2026-05-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-148-KCurrent report2026-05-14SEC
2026-04-03UPLOADUpload SubmissionSEC
2026-03-20CORRESPSEC
2026-03-2010-K/A2025-06-30SEC
2026-02-24UPLOADUpload SubmissionSEC
2026-02-128-KCurrent report2026-02-12SEC
2026-02-1210-QQuarterly report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-02-11424B3SEC
2026-02-10EFFECTEffectiveness filing by commission orderSEC
2026-02-06CORRESPSEC
2026-02-06UPLOADUpload SubmissionSEC
2026-01-30S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-01-29SCHEDULE 13G/ASEC
2026-01-264Statement of changes in beneficial ownership of securities2026-01-22SEC
2025-12-294Statement of changes in beneficial ownership of securities2025-12-23SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-122.44M600
2025-1120.00M100

Institutional holders

Manager% owned
MONTANOVA CAPITAL, LLC33.62%
Nantahala Capital Management, LLC8.66%
Jupiter Topco LLC7.21%
FRANKLIN RESOURCES INC7.02%
ADAGE CAPITAL PARTNERS GP, L.L.C.6.17%
RA CAPITAL MANAGEMENT, L.P.5.39%
BlackRock, Inc.4.10%
Simplify Asset Management Inc.2.87%
VANGUARD CAPITAL MANAGEMENT LLC2.78%
INFINITUM ASSET MANAGEMENT, LLC2.69%

Funds

Fund% owned
Simplify Health Care ETF2.93%
Franklin Biotechnology Discovery Fund2.90%
VANGUARD TOTAL STOCK MARKET INDEX FUND1.89%
iShares Russell 2000 ETF1.55%
Franklin Small Cap Growth Fund1.04%
VANGUARD EXTENDED MARKET INDEX FUND0.82%
Fidelity Small Cap Index Fund0.68%
iShares Russell 2000 Value ETF0.55%
Fidelity Extended Market Index Fund0.37%
VANGUARD RUSSELL 2000 INDEX FUND0.36%

OakChart. BNTC. Cached 15 minutes.